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Abstract
Background—Intensification of pharmacotherapy in persons with poorly controlled chronic
conditions has been proposed as a clinically meaningful process measure of quality.
Objective—To validate measures of treatment intensification by evaluating their associations
with subsequent control in hypertension, hyperlipidemia, and diabetes mellitus across 35 medical
facility populations in Kaiser Permanente, Northern California.
Design—Two-level, hierarchical analyses of associations of improvements in facility-level
treatment intensification rates from 2001 to 2003 with patient-level risk factor levels at the end of
2003.
Patients—515,072 and 626,130 members (age > 20 years) with hypertension, hyperlipidemia,
and/or diabetes mellitus in 2001 and 2003, respectively.
Measurements—Treatment intensification for each risk factor defined as an increase in number
of drug classes prescribed, of dosage for at least one drug, or switching to a drug from another
class within 3 months of observed poor risk factor control.
Results—Facility-level improvements in treatment intensification rates between 2001 and 2003
were strongly associated with greater likelihood of being in control at the end of 2003 (p≤0.01 for
each risk factor) after adjustment for patient- and facility-level covariates. Compared to facility
rankings based solely on control, addition of percentages of poorly controlled patients who
received treatment intensification changed 2003 rankings substantially: 14%, 51%, and 29%) of
the facilities changed ranks by 5 or more positions for hypertension, hyperlipidemia, and diabetes,
respectively.
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Conclusions—Treatment intensification is tightly linked to improved control. Thus, it should be
an effective process measure for motivating quality improvement and for measuring clinical
performance.
Keywords
diabetes mellitus; hypertension; hyperlipidemia; quality of health care; cardiovascular disease
Introduction
Morbidity and mortality from cardiovascular diseases are largely attributable to poor control
of hypertension, hyperlipidemia, and diabetes mellitus, along with cigarette smoking (1-5).
Despite the availability of evidence-based treatments (6-10), recent reports (11-14) find
persistent suboptimal control of blood pressure, LDL-cholesterol and hemoglobin A1c.
Moreover, physicians often fail to intensify pharmacologic treatment appropriately in the
face of poor risk factor control (15-21). “Clinical inertia” has been suggested as an
explanation for poor control and a target for quality improvement (15,22-23).
Kerr (24,25) and others (15) have suggested that measurement and feedback of the
frequency with which pharmacotherapy is intensified in patients with poorly controlled risk
factors may represent a useful approach to clinical quality measurement and improvement.
Voorham et al (26) found that simple measures of proportions of patients in control for
hypertension, hyperlipidemia and diabetes underestimate the proportions receiving high
quality clinical care and concluded that more sophisticated measures including measures of
treatment intensification could improve quality assessment. Considering a process measure
such as treatment intensification along with measures of risk factor control addresses
concerns that case-mix differences rather than variation in clinical quality could explain
observed differences in control and may reduce provider reluctance to include difficult-to-
treat patients in their panels. It may also reduce risks of overtreatment and adverse
consequences from an overzealous focus on tight risk factor targets (27,28).
Because numerous clinical trials demonstrate that treatment intensification leads to
improved hypertension, hyperlipidemia and diabetes control, intensification measures have
been called “tightly linked” (24,25) or “evidence-based,” in contrast to simpler non-
evidence-based processes such as rates of testing. However, linkage of treatment
intensification rates in populations, as would be used in quality measurement, with better
rates of risk factor control has not yet been demonstrated.
We reported treatment intensification rates (29) in patients with poorly controlled
hypertension, hyperlipidemia, or diabetes mellitus for Kaiser Permanente Northern
California during 2003. Intensification rates were somewhat higher than in earlier reports
(15, 18-19), but room for further improvement remained and significant variation in rates
was observed across the 39 medical facilities within this system. In this paper, we test
hypotheses that variation among these facilities in treatment intensification rates for
hypertension, hyperlipidemia, and diabetes mellitus are associated with differences in levels
of risk factor control.
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Methods
Study Population
The study population has been described previously (29,30). We identified all adult
members (age ≥ 20 years) of Kaiser Permanente Northern California who were recognized
by clinicians as having hypertension, diabetes mellitus, and/or hyperlipidemia during two
18-month periods (June 1, 2000 - December 31, 2001 and June 1, 2002 - December 31,
2003), and were continuously enrolled for at least the final 4 months of either period. Kaiser
Permanente is an integrated health care system providing comprehensive care to a diverse
population (31) of approximately 3.2 million members in Northern California.
Identifying criteria for each condition are given in the Appendix. Patients with elevated risk
factor values were not included if no evidence was found of physician awareness (i.e.,
recorded diagnoses, prescriptions for disease-specific medications, or in the case of diabetes
a follow-up hemoglobin A1c test). Cutpoints for identifying hyperlipidemia varied
depending on patients' cardiovascular disease risk status, using ATP-III guidelines (7).
Assignment of risk required identification of previous coronary heart disease from inpatient
and outpatient diagnoses and calculation of 10-year coronary heart disease risk for each
patient. Totals of 515,072 and 626,130 members met criteria for hypertension,
hyperlipidemia, and/or diabetes in 2001 and 2003, respectively.
Enrollment and demographic data (age, sex) were obtained from membership databases.
Burden of co-morbid illness was assessed using the DxCG Diagnostic Cost Group risk
adjustment methodology, (32,33) which is based on 1-year hospital discharge and
ambulatory diagnoses (for 2003). Self-reported race/ethnicity was found for approximately
88% of all members using information from birth, maternity and hospitalization records and
responses to member satisfaction surveys.
Members were assigned to a facility using the location of their primary care provider, as
recorded in system databases. We excluded 20,134 (3%) otherwise eligible patients from 4
small facilities that opened after the end of 2001, because change scores could not be
calculated for these facilities, and an additional 2.5% of eligible patients who could not be
linked with a primary care provider.
Definitions of Control
Risk factor control was assessed for all patients with each condition, based on last recorded
values in 2001 and 2003 from laboratory (LDL-cholesterol and hemoglobin A1c) and
encounter (blood pressure) databases. We have previously shown that last readings are
equivalent to means of all readings within a year for aggregate measures.(34) Values were
available for at least 95 percent of those with hypertension and for 94% of those with
hyperlipidemia or diabetes in each year. Persons with no values for a condition were
excluded only from analyses of that condition.
For each condition, we defined two levels of control (Table 1). “Stringent control” was
defined using the most rigorous guideline targets in place in 2003. “Near control” was then
defined using somewhat higher cutpoints that corresponded with the action levels used in
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calculating treatment intensification (see below). “Poor control” designates values above the
cutpoints for near control. Definitions of control also varied depending on risk for both
LDL-cholesterol and blood pressure control (Table 1). In December 2002, a switch to the
IFCC reference standard promoted by the National Glycohemoglobin Standardization Group
(35) at Kaiser Permanente's regional laboratory effecting an immediate decrease of 0.3
percentage points in Hb A1c values. This affected all facilities simultaneously, but led to a
prompt 10 percentage-point improvement in the percentage of patients with A1c values
<7%.
Treatment intensification
Treatment intensification was identified from pharmacy databases and calculated for all
patients who met criteria for poor control at any point during either year. We did not
measure intensification for those in near control out of concern that an intensification
measure in these patients could encourage over-treatment and adverse effects. Intensification
was defined as an increase in number of drug classes prescribed, increased dosage of at least
1 medication, or a switch to another medication in a different therapeutic class within 3
months (and 6 months) following the initial observation of poor control. Follow-up was
extended into 2004 to detect intensification when poor control was first identified in the last
months of 2003.
Seven medication classes were tabulated for hypertension, 5 for hyperlipidemia, and 5 for
diabetes (29). Daily dosages were categorized as low, medium, or high based on package
insert recommendations and inspection of actual dosage distributions. Dosages at or below
recommended initial starting doses were categorized as low; those within the recommended
maintenance range as intermediate; and dosages at or above the high end of the
recommended range as high. To identify intensification, comparison was made to
medications dispensed during the four-month period before poor control was noted. We
included switches to a medication in a different class as treatment intensifications because
they represent physician responses intended to render therapy more “intense” either by
changing to a more effective or better tolerated medication. Only 11%, 2%, and 4% of
“intensifications” for hypertension, hyperlipidemia and diabetes were solely switches among
classes. We excluded all patients with diabetes who were using insulin prior to the
observation of poor control because day-to-day adjustments in insulin can not be identified
in prescription databases.
Data Analyses
We examined whether longitudinal improvements in treatment intensification were
associated with improvements in control for each condition. Primary analyses treated both
stringent and near control as being in control, because these were the cutpoints used in
calculating treatment intensification. However, we repeated all analyses to see whether
treatment intensification as calculated was also associated with rates of stringent control.
We examined inter-facility differences in proportions of patients in stringent and stringent/
near control and proportions of poorly controlled patients receiving treatment intensification
for each time period and condition. Systolic rather than diastolic blood pressure control was
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examined because of its greater importance in predicting coronary heart disease risk.(36,37)
Only 16% of all hypertensive patients had diastolic pressure ≥ 90 mmHg in 2003 and of
these, 72% of those also had elevated systolic pressure.
Unadjusted associations of facility-level improvements in treatment intensification from
2001 to 2003 with improvements in control rates were assessed using Spearman rank
correlations. To adjust for case-mix differences and baseline differences in control, we then
constructed two-level (38-40) models with improvement in facility-level treatment
intensification rates from 2001 to 2003 as the main independent variables and patient-level
control (stringent/near control vs. poor control) at the end of 2003 as dependent variables.
We used Generalized Linear Models (SAS PROC MIXED with GLIMMIX Macro (Version
9.1)) and included random effects for facility and for provider nested within facility. Two
facility-level covariates were included as fixed effects: the percent of patients in control in
2001 and the percent of poorly controlled patients receiving treatment intensification in
2001. Patient-level fixed effects included age, sex, and race-ethnicity, and the DxCG score.
Race/ethnicity was included because African-American patients are consistently found to
have higher levels and more difficulty controlling each of these risk factors (41-43). Race/
ethnicity distributions differed greatly by facility and treatment intensification has been
previously shown to vary by race/ethnicity (29). Hyperlipidemia models were further
adjusted for patients' prior history of coronary heart disease and hypertension models for
prior history of target organ disease as defined by JNC VI (44), because these characteristics
altered target LDL-cholesterol (7) and blood pressure levels (43) in place during this period,
may have differed between facilities, and therefore could confound facility comparisons of
treatment intensification and control.
Model results are presented as adjusted odds ratios for control associated with a 1
percentage point change in the facility treatment intensification rates from 2001 to 2003. To
facilitate interpretation of these results, we used all model coefficients to calculate predicted
probabilities of being in control at two different facilities: one with the average observed
improvement in treatment intensification and the other with 5 percentage points greater
improvement. This 5% difference represents one third to one half of the observed ranges
across facilities for increases in treatment intensification for the three risk factors. The
predicted differences in control (and 95% confidence intervals) are presented.
In sensitivity analyses, we examined associations of treatment intensification with likelihood
of being in stringent control (rather than in stringent/near control). We also re-fit models
after deleting small percentages whose only treatment intensification was switching to a
medication of a different class; and after lengthening the period in which treatment
intensification could occur to 6 months.
To study the impact of measuring treatment intensification on performance ranking, we
compared crude rankings of the 35 facilities by proportions in control (stringent/near
control) at the end of 2003 with rankings based on combined measures of proportions in
control or receiving treatment intensification. Patients who received treatment intensification
during the year and were in control by their last reading were counted as in control, not as
having received treatment intensification. We also calculated the mean change in rankings
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and the proportion of facilities that changed by 5 or more rank positions when the combined
measure was substituted. This study was reviewed and approved by Kaiser Permanente's
Institutional Review Board.
Results
Numbers of persons meeting criteria for each condition increased between 2001 and 2003
(Table 2), especially for hyperlipidemia, but there were no important changes in age, gender
or race distributions, nor in disease severity for hypertension or hyperlipidemia. Sample
sizes per facility were large, the smallest cell being 240 diabetic patients at one facility in
2001. Proportions of patients who were African-American varied widely across facilities as
did mean age and levels of comorbidities.
Levels of Control and Treatment Intensification
Control improved for each condition from 2001 to 2003 (Table 2) and varied substantially
across facilities in both years. For hypertensive patients, 48% and 78% met criteria for
stringent control and stringent/near control of systolic blood pressure, respectively, in 2003;
45% and 77% of those with hyperlipidemia met these criteria for LDL-cholesterol; and 51%
and 77% of diabetic patients did so for hemoglobin A1c. Improvements in control appeared
greatest for hemoglobin A1c, but as much as half of this was due to the change in laboratory
standardization.
On average, treatment intensification for hypertension increased by 7 percentage points from
2001 to 2003; increases were smaller for hyperlipidemia and diabetes. These changes varied
from less than 1% to a 15.2% increase for hypertension; from a 9% decrease to a 9.4%
increase for hyperlipidemia, and from a 4.9% decrease to 7.4% increase for diabetes.
Association of treatment intensification with control
Facility-level increases in treatment intensification from 2001 to 2003 were associated with
concurrent improvements in control rates (stringent/near control) for each condition.
Correlations with improvements in stringent control were of similar size for hypertension
and hyperlipidemia, but somewhat weaker for diabetes (Spearman rank correlations: 0.53, p
< 0.01 for hypertension; 0.42, p=0.01 for hyperlipidemia; 0.20, p=0.24 for diabetes)
In two-level models, improvement in a facility's treatment intensification rate from 2001 to
2003 was positively associated with a patient's likelihood of being in control (stringent/near
control) at the end of 2003 (p<0.01 for each condition) after adjustment for facility- and
patient-level covariates (Table 3). Compared with the average improvement, a 5% greater
increase in the facility's treatment intensification rate predicted a 1.1% greater likelihood of
systolic blood pressure control; a 1.1% greater likelihood of LDL-cholesterol control; and a
1.8% greater likelihood of hemoglobin A1c control. These associations are remarkably
strong considering that only 23-25% of patients were eligible for treatment intensification,
while control was measured in the entire affected population. Higher facility-level control
and treatment intensification rates in 2001 were also strong, independent predictors of
patient control in 2003.
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Associations were of similar size when the dependent variables were changed to being in
stringent control (adjusted OR's: systolic blood pressure: 1.012, p=0.01; LDL-cholesterol:
1.013, p=0.018; and hemoglobin A1c, 1.020, p=0.0005); when switching to a medication in
a different class was not counted as treatment intensification; and when the period for
identifying treatment intensification was lengthened to 6 months.
Among patient-level predictors, greater age was associated with poorer control of systolic
blood pressure but better control for LDL-cholesterol and hemoglobin A1c. Female gender
was associated with slightly lower odds of blood pressure control, but not with LDL-
cholesterol or hemoglobin A1 control. Compared with white patients, all non-white race/
ethnicity groups were substantially less likely to be in control for A1c values. African- and
Native-Americans were also less likely to be in control for hypertension and hyperlipidemia,
but Asian patients were more likely to be in control for each. Greater levels of comorbidity
were associated with better blood pressure control, but not with better LDL-cholesterol or
hemoglobin A1c control.
Comparison of rankings Show facility rankings by proportions of patients in stringent/near
control. The non-monotonic pattern of heights for the full vertical bars indicates that
including the additional proportions of poorly controlled patients receiving treatment
intensification changes facility rankings. Spearman rank correlations between these two
ranking approaches were lower and average changes in ranking greater for hyperlipidemia
and diabetes than for hypertension (Table 4).
Discussion
Clinical inertia remains an important cause of poor risk factor control in chronic conditions
(20,21). Clinical uncertainty and competing demands have been identified as contributors to
inertia (45). Nevertheless, the present findings confirm that clinical populations
experiencing greater increases in treatment intensification rates for hypertension,
hyperlipidemia and diabetes mellitus had better control of these conditions, strengthening
the case that greater emphasis on treatment intensification would be useful for quality
improvement (24-26). The strength of the associations we observed was large for each
condition. Five percent improvements in treatment intensification, calculated in the 32 to
38% of patients eligible for intensification, led to 1.1 to 1.8% improvements in control for
the entire population. Associations were equally strong whether we used less stringent or
stricter definitions of control.
Although many clinical trials demonstrate that treatment intensification improves risk factor
control in individual patients, it could still be argued that when treatment intensification is
aggregated to the population level, higher rates may not necessarily be equivalent to better
control. Conceivably, the wrong patients could be intensified or the wrong medications used.
Non-adherence to medications could undermine the effects of intensification. The present
analyses reduce these concerns and suggest that, on average, physicians groups or health
plans with higher intensification rates for these conditions are achieving better control.
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We used two-level analyses, relating facility-level measures of treatment intensification to
patient-level outcomes, rather than individual-level analyses for two reasons. It was the
population measure of treatment intensification that we wished to evaluate. Secondly, two-
level analyses are less biased than individual-level observational studies by confounding by
indication (38-40). Thus, in a recent individual-level study, (46) patients with poorly
controlled hypertension who received treatment intensification appeared more likely to
remain poorly controlled than those who did not. In a second study (21), only a weak,
nonsignificant association of treatment intensification with better hypertension control was
found, even after controlling for baseline blood pressure levels. Decisions to intensify
treatment in individual patients involve consideration of factors that strongly confound
observational analyses. By focusing on practice variation between facilities rather than
between patients, two-level analyses reduce such confounding.
More generally, our findings support the concept that linked process measures offer an
attractive, additional approach for quality improvement. Focusing on and improving simpler
process measures is often unaccompanied by improvements in meaningful outcomes
(47-51). Clinicians and health care systems can be more confident that a focus on improving
linked process measures will translate to benefit for patients.[1] Such measures have
additional advantages in that the action required of physicians or systems to improve quality
(in this case, intensifying treatment) is implicit in the measure. They can be tailored to focus
on optimal medication or clinical strategies for improving long-term outcomes.
Despite these attractive features, treatment intensification measures as constructed here
would have serious limitations as external performance measures for health plans, physician
groups, or individual physicians. Their measurement requires both risk factor and
prescribing data, which are not readily available in less integrated delivery settings without
electronic health records (EHRs). Conceivably, chart reviews could be adapted to obtain this
added information, but standardized measurement would also require complex
categorization of multiple drugs and combination medications into treatment classes,
standard quantification of dosage increases, and measurement of risk-specific target levels.
Each of these would require updating over time.
A second limitation is that the treatment intensification measures we constructed include
only the minority of patients who are in poor control. As control improves, these
denominators shrink. Using stricter definitions of control could enlarge denominators (i.e,
by including the larger numbers in “near control”), but we would be concerned that in a
context of performance reporting and incentivization, more stringent cutpoints could lead to
adverse effects of overmedication in patients who would stand to gain very little (27,28).
However, in the context of internal quality improvement efforts, where there is less risk of
perverse incentives, broader definitions of poor control could be examined. For example,
patients who are in near control on two consecutive measures could be included, reasoning
that non-pharmacologic efforts do not appear to be helping.
An additional limitation of these measures is that systems or groups with higher proportions
already in control would not be recognized and could even be penalized if their smaller
numbers of remaining poorly controlled patients were more resistant to intensification or
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more likely to have valid reasons not to intensify, such as intolerance to some medication
classes or known non-adherence to current medications. Measures that combine proportions
in control with proportions of remaining patients who received treatment intensification
(25,26) capture both aspects of clinical quality and were shown in this study to change
performance rankings compared with simpler measures of percent in control.
Although the associations we observed were robust, the measures could be refined in several
ways in settings where data are available. Credit could be given for the small percentages of
patients (3% of persons with diabetes or hyperlipidemia; 11% of those with hypertension)
who returned to control without changes in pharmacotherapy by their next reading. (29)
Patients who appeared to be nonadherent to present medications could be excluded before
calculating intensification rates, as treatment intensification may be inappropriate for this
group (52). Credit could be given for small percentages (well below 10%) of hypertensive or
hyperlipidemic patients already on maximal medical therapy (20,29) and for persons with
contraindications to some medication classes or with comorbidities that may make
intensification inappropriate. (53) Measures could ultimately be refined to distinguish
among treatment intensification choices, possibly giving more credit for using recommended
next steps in treatment intensification and not crediting intensifications that have been
shown to be harmful. Lastly, prescriptions written rather than prescriptions filled may be a
more direct measure of clinical performance, although data from Kaiser Permanente's EHR
indicate that more than 95% of physician-ordered prescriptions for new medications are
filled at least once (54) and thus captured in prescription database. Each of these refinements
could enhance the credibility of intensification measure with providers. A persistent
limitation without obvious solution is the inability, in either EHR or prescription databases,
to capture day-do-day intensifications of insulin therapy.
In conclusion, improvements in rates of treatment intensification for patients with poorly
controlled hypertension, hyperlipidemia, or diabetes mellitus are directly related to
improved population risk factor control. These measures deserve further consideration for
use in improving clinical quality of care.
Acknowledgments
Funded in part by a research grant from Pfizer Pharmaceuticals, Inc. By contract, first-author (JVS) retained right to
publish findings without approval from Pfizer. Dr. Rodondi supported by a grant from the Swiss National
Foundation (PBLAB-102353). Dr. Kerr's time was funded in part by the VA HSR&D Quality Enhancement
Research Initiative for Diabetes Mellitus (DIB 98-001) and by the Measurement Core of the Michigan Diabetes
Research and Training Center (P60DK-20572).
Appendix 1. Diagnostic Criteria for Diabetes Mellitus, Hypertension, and
Hyperlipidemia
Diabetes Mellitus (one of the following)
1. at least one prescription of insulin or an oral hypoglycemic agent; or
2. at least two outpatient diagnoses of diabetes mellitus; or
3. one outpatient diagnosis of diabetes mellitus plus ≥ 1 Hemoglobin A1c ≥ 7%; or
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4. at least one hospital discharge with a primary diabetes-related diagnosis (ICD-9
code 250.X).
Hypertension (one of the following)
1. at least one prescription for an anti-hypertensive medication plus an outpatient
diagnosis of hypertension; or
2. at least two outpatient diagnoses of hypertension; or
3. at least one prescription for an anti-hypertensive medication plus one or more
elevated outpatient blood pressure readings (≥ 140 mm Hg systolic, or ≥ 90 mm Hg
diastolic); or
4. at least one outpatient diagnosis of hypertension plus at least one blood pressure
reading of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic;
Hyperlipidemia (one of the following)
1. at least one prescription for an anti-lipemic agent; or
2. Outpatient diagnosis of hyperlipidemia/hypercholesterolemia with an LDL-
cholesterol value ≥ risk-appropriate cutpoint value*; or
3. Outpatient diagnosis of hyperlipidemia/hypercholesterolemia with a prior LDL-
cholesterol value ≥ risk-appropriate cutpoint value1 (within 2 years prior to
7/01/00).
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Table 1
Risk-specific Definitions of Control for Systolic Hypertension, Hyperlipidemia, and
Diabetes Mellitus
Condition and Risk Category Measure Stringent control Near control Poor control
Systolic Hypertension
 No diabetes and no target organ
disease†
2 consecutive systolic blood pressures
(mm Hg)
< 140 140-159 ≥ 160
 With diabetes or target organ disease < 130 130-139 ≥ 140
Hyperlipidemia
Low Risk: No diabetes or coronary heart
disease, < 2 coronary heart disease risk
factors
LDL-cholesterol, (mmol/L (mg/dL)) < 4.2 (160) 4.2-5.0 (160-190) ≥ 5.0 (190)
Moderate Risk: 2 coronary heart disease
risk factors, but 10-yr Framingham risk <
20%
< 3.4 (130) 3.4-4.1 (130-159) ≥ 4.2 (160)
High Risk: With diabetes or coronary
heart disease, or ≥ 2 coronary heart
disease factors and 10-yr Framingham
risk ≥ 20%
< 2.6 (100) 2.6-3.3 (100-129) ≥ 3.4 (130)
Diabetes
Hemoglobin A1c (%) < 7% 7.0–7.9% ≥ 8%
*
DM: diabetes mellitus;
†
TOD: target organ disease (cardiovascular or renal disease, 44);
‡SBP: systolic blood pressure;
§CAD: coronary artery disease
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Table 2
Characteristics of Patients, Levels of Control, and Rates of Treatment Intensification
(with Inter-facility Ranges) for Hypertension, Hyperlipidemia, and/or Diabetes Mellitus,
across 35 Medical Facilities Kaiser Permanente Northern California, 2001 and 2003
Hypertension: Total N (inter-facility range)
2001
381,671 (988 – 25,556)
2003
478,320 (1,287 – 29,592)
 Mean Age (standard deviation) (inter-facility range) 62.9 (13.7) (57.3 – 69.2) 62.7 (13.9) (58.2 – 68.6)
 % Female (inter-facility range) 55.4 (50.2 – 59.6) 54.9 (51.0 – 58.3)
 % African American (inter-facility range) 11.0 (0.2 – 45.2) 10.8 (0.4 – 45.3)
 % with diabetes or target organ disease (inter-facility range) 39.9 (30.6 – 43.5) 41.2 (32.1 – 44.9)
 Mean SBP in mm Hg (standard deviation) (inter-facility range) 144.3 (17.1) (138.7 - 149.5) 139.1 (15.8) (136.1 – 142.8)
 % in stringent control for SBP (inter-facility range) 34.0 (25.0 - 47.9) 48.1 (34.9 - 56.2)
 % in stringent/near control for SBP (inter-facility range) 66.5 (56.7 – 77.0) 77.5 (68.5 – 84.6)
 % of poorly controlled receiving treatment intensification within 3 months
(inter-facility range) 47.7 (40.2 - 53.8) 54.4 (47.3 – 61.1)
Hyperlipidemia: Total N (inter-facility range) 211,257 (594 – 13,708) 321,549 (875 – 19,669)
 Mean Age (standard deviation) (inter-facility range) 62.7 (11.9) (58.2 – 67.9) 62.5 (12.5) (58.6 – 68.0)
 % Female (inter-facility range) 45.7 (40.1 – 51.5) 47.4 (43.2 – 51.4)
 % African American (inter-facility range) 7.7 (0.4 - 34.0) 8.2 (0.1 – 35.7)
 % High risk (inter-facility range) 60.0 (51.7 – 65.8) 59.9 (53.6 – 65.1)
 % Moderate risk (inter-facility range) 21.5 (17.6 – 25.5) 22.6 (19.9 – 25.6)
 Mean LDL-c in mg/dL (standard deviation) (inter-facility range) 126.7 (38.7) (120.1 – 132.1) 118.2 (36.2) (113.1 – 122.7)
 % in stringent control for LDL-c (inter-facility range) 34.6 (30.4 – 41.1) 44.8 (37.9 – 53.9)
 % in stringent/near control for LDL-c (inter-facility range) 67.5 (62.7 – 73.9) 76.5 (69.2 – 82.3)
 % of poorly controlled receiving treatment intensification within 3 months
(inter-facility range) 45.5 (37.0 – 52.1) 46.9 (40.3 – 56.0)
Diabetes: Total N* (inter-facility range) 128,101 (240 – 8,124) 151,401 (313 – 9,366)
 Mean Age (standard deviation) (inter-facility range) 60.7 (13.2) (56.6 – 68.7) 61.2 (13.3) (57.8 – 67.2)
 % Female (inter-facility range) 46.7 (40.6 – 52.1) 47.0 (40.4 – 52.5)
 % African American (inter-facility range) 11.9 (0.4 – 49.1) 11.4 (0.4 – 47.9)
 Mean Hb A1c in % (standard deviation) (inter-facility range) 7.9 (1.8) (7.4 – 8.4) 7.3 (1.5) (6.9 – 7.5)
 % in stringent control for Hb A1c (inter-facility range) 32.6 (25.9-44.6) 51.1 (45.2-62.0)
 % in stringent/near control for Hb A1c (inter-facility range) 61.5 (51.0 – 72.1) 77.1 (70.5 – 86.3)
 % of poorly controlled patients receiving treatment intensification within 3
months (inter-facility range)* 56.3 (49.1-63.7) 56.9 (48.3 – 66.1)
*
Patients on insulin during 4 months before elevated value are excluded from all analyses
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Table 4
Comparisons of Facility Rankings based on % in Control† with Rankings based on % in
Control or Intensified
Condition Spearman Rank Correlations
Mean Absolute Change in Rank
(SD)
% of the 35 Facilitie changing by ≥ 5 ran
positions
Hypertension 0.96 2.34 (1.83) 14.2%
Hyperlipidemia 0.67 6.34 (5.29) 51.4
Diabetes Mellitus 0.93 3.09 (2.33) 28.6
†Control defined as stringent/near control.
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